Galmed Pharmaceuticals to execute 1-for-8 reverse share split Aug. 19, 2026

• Galmed Pharmaceuticals will execute a 1-for-8 reverse share split of its ordinary shares.
• Post-split trading on the Nasdaq Capital Market is set to begin on Aug. 19, 2026.
• Issued and outstanding shares are expected to fall to about 1,041,565 from 8,332,518, subject to fractional-share treatment.
• Authorized share capital will be 112,500,000 ordinary shares with par value NIS 14.40 per share.
• Outstanding warrants and options will be adjusted proportionately; the new CUSIP for the ordinary shares will be M47238205.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Galmed Pharmaceuticals Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-038436), on August 14, 2026, and is solely responsible for the information contained therein.